Senior Director, US Rare Disease Value and Access

Job title: Senior Director, US Rare Disease Value and Access

Location: Cambridge, MA

About the job

Join the team transforming care for people with immune challenges, rare diseases, cancers, and neurological conditions. In Specialty Care, you’ll help deliver breakthrough treatments that bring hope to patients with some of the highest unmet needs. 

As Senior Director, US Rare Disease Value and Access within our US Rare Disease Leadership Team, you'll own payer-focused access strategy across a $2.2B business with 7 marketed products and 2 pipeline launches, including a landmark AATD therapy in 1H 2027. You'll lead pricing, contracting, reimbursement, and GTN strategy to maximize formulary adoption and patient access. This role is a member of the US Leadership Team and reports directly to the General Manager. Ready to get started?

You'll be joining Sanofi's US Rare Disease business at a pivotal moment—managing market access for a portfolio with clear growth trajectory to $3.1B by 2030, leading payer strategy for breakthrough therapies, and ensuring patients can access innovative treatments without delay.

About Sanofi

We're an R&D-driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Our deep understanding of the immune system – and innovative pipeline – enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve people's lives.

Main responsibilities:

• Partner with GM and senior leadership to set direction for pricing, contracting, GTN, and reimbursement across rare disease portfolio

• Develop evidence-based market access strategies that maximize formulary adoption and patient access

• Create compelling value propositions for payers, providers, and key stakeholders

• Oversee and optimize GTN across the therapeutic area—pricing, rebates, and discounts by channel

• Monitor GTN performance and deliver recommendations to senior leadership to protect profitability

• Collaborate with Finance, Forecasting, Trade, Legal, and Patient Support Services to improve net sales

• Lead GTN pull-through across all channels and geographies based on formulary position

• Anticipate changes in regulatory and reimbursement landscape; ensure sustained compliance and access

• Develop primary payer research and advisory board programs to close market access knowledge gaps

• Champion launch readiness for landmark AATD therapy (1H 2027) across payer, access, and reimbursement dimensions

• Monitor competitive landscape and payer behavior in partnership with Business Insights & Solutions

• Define KPIs and track progress against access and financial targets

• Balance brand objectives and patient access priorities when they are in conflict

• Build, develop, and lead a high-performing team of 2 direct reports

About you

Role Overview:

• The Senior Director, US Rare Disease Value and Access owns the value, evidence, pricing, and reimbursement strategy that turns an approved rare disease therapy into a covered, affordable, accessible one. The role spans HEOR and evidence generation, pricing and contracting, payer engagement, and policy — working backwards from what payers need to be convinced of value, often with limited trial data. In rare disease, access is not a downstream function: it is a strategic driver that shapes the commercial case from before launch.

• Beyond access expertise, the Head of Access Strategy must lead the function through the new era of AI-augmented evidence and value work. The six behaviors below apply to the whole leadership team; the ones this role leans on hardest are highlighted.

Leadership Behavior:

What It Means in the New Era

1. Leads with AI-augmented judgment

• Uses data and AI to decide faster and better — while owning the judgment calls AI cannot make.

2. Orchestrates across boundaries

• Delivers through influence, shared goals, and trust as functional silos dissolve — not through positional control.

3. Drives change and adoption

• Pulls the team through AI and digital change, creates psychological safety to experiment, and names resistance rather than tolerating it.

4. Obsesses over the patient outcome

• Anchors decisions to the patient's find-to-adherence journey, not fu